Background Limited evidence is available on the impact of socioeconomic factors on drug prescriptions for psoriasis. Objectives To investigate factors influencing prescription of conventional vs. biological treatment for patients with psoriasis, based on the Italian Psocare registry, with a special focus on socioeconomic factors. Methods This was a cross-sectional study evaluating the baseline data of patients included in the Psocare registry. All of the consecutive adult patients with a diagnosis of chronic plaque psoriasis or psoriatic arthritis who were prescribed a systemic treatment for psoriasis at participating centres were included in this study. Univariate and multivariate analyses of the baseline factors associated with a biologics prescription were performed. Results From September 2005 to September 2009, 12 838 patients were identified. A multivariate analysis revealed that, among other factors, completing a level of education higher than lower secondary school and being employed as a manager or a professional were independent factors associated with a biologics prescription at entry in the registry. Additional analyses on the association between these two variables and a severe psoriasis condition [Psoriasis Area Severity Index (PASI) score > 20] revealed a significantly increasing trend of severe disease towards lower educational attainment, while unemployed patients were more likely to have a more severe condition compared with the other categories of workers. Conclusions We documented inequalities of drug prescriptions for psoriasis in Italy, with a trend towards a higher frequency of prescription for more expensive biologics in higher socioeconomic sectors of the population.
Inequalities in health can be defined as unfair systematic differences in health care and health status among individuals. 1, 2 Disparities in healthcare provisions and outcomes such as morbidity and mortality have been noted, for example, between different social groups, between urban and rural populations, and between different geographical areas in the same country. 3, 4 Many of these discrepancies cannot be accounted for by biological factors. Instead, a major part is played by socioeconomic and environmental factors, including lifestyles. Several treatment options are available for psoriasis. The annual cost of these treatments shows large variation. In particular, more targeted therapies, including biological agents (such as tumour necrosis factor-a blockers), are very expensive and their prescription is restricted to patients not responding or having contraindications to the less expensive, conventional agents.
To date only two studies, from the U.S.A. have focused attention on the impact of socioeconomic factors on drug prescriptions in psoriasis. One study, from the Medicare social insurance programme, documented that people without access to a Medicare Part D low-income subsidy had a much lower chance of having received biologics than those with such access. 5 The other study, limited to a single academic medical centre, documented that difficulty in obtaining biologics was associated with younger age, lower income level and lack of insurance. 6 The aim of our study was to investigate the factors influencing the prescription of conventional treatments vs. biological treatments for patients with psoriasis, based on the Italian Psocare registry, with a special focus on socioeconomic factors, which may reflect inequalities in health care. The Psocare registry systematically recruits all patients at the reference centres who are starting a new systemic treatment for psoriasis in Italy. 7 
Patients and methods
This was a cross-sectional study evaluating the baseline data of patients who were included in the Psocare registry. In this study, 155 dermatology outpatient clinics participated (Appendix S1; see Supporting Information). These clinics were located across Italy and were appointed by the Italian Regional Health Authorities as reference centres for the treatment of moderate-to-severe psoriasis. The Italian National Health Service (NHS) was established in 1978 and it is founded on the principles of universal coverage, social financing through the use of general taxation, and nondiscriminatory access to health care services. 8 The study was conducted according to Declaration of Helsinki principles and received ethics committee approval of the participating centres. The Psocare registry's goals and methods have been described in detail elsewhere. 7 The main outcome of this study was to describe the factors associated with the choice of systemic treatment at entry in the registry.
Patients
All consecutive adult patients (aged ≥ 18 years) who were clinically confirmed with a diagnosis of chronic plaque psoriasis or psoriatic arthritis (PsA) and who were prescribed a new systemic treatment for psoriasis for the first time in their life at the participating centres were included in this study. To get reimbursement by the NHS, a compulsory registration within the Psocare registry was required for subjects receiving a biological therapy; conventional treatment could be prescribed outside the registry.
The conventional treatments considered included acitretin, ciclosporin, methotrexate, and psoralen and ultraviolet A (PUVA) therapy, while etanercept, infliximab, adalimumab and ustekinumab were considered as biological treatments.
According to the registered indications, only those patients with moderate-to-severe psoriasis [Psoriasis Area Severity Index (PASI) ≥ 10] with failure of, contraindication to or adverse events under conventional systemic agents (e.g. ciclosporin, acitretin, methotrexate and PUVA) were eligible for biological therapy (e.g. infliximab, etanercept and adalimumab). Patients receiving combination treatments or off-label dosages and patients who had unspecified baseline treatments were excluded from this study. All of the patients gave written informed consent before being included in this study.
Data collection
The study investigators registered the patients on a web-based electronic data collection system endowed with internal quality controls, which also guaranteed confidentiality. Data collected at baseline included (i) demographic details and personal habits (e.g. smoking, average alcohol consumption, educational attainment and employment status); (ii) history of current or previous main comorbidities and medications; (iii) dermatological and family history of psoriasis and/or PsA; and (iv) severity of psoriasis, any drugs prescribed, and results of the laboratory tests performed prior to the prescription. PASI was adopted as the measure of disease severity. In addition the patient's perceived severity was rated from zero to 10 using a standard visual analogue scale (VAS). The Charlson comorbidity index (CCI) was also used as a surrogate measure for overall comorbidity.
Statistical analysis
For descriptive purposes, continuous data are presented as mean AE SD, and categorical variables as numbers with percentages. Continuous variables were categorized, for analysis purposes, using clinically meaningful thresholds as cut-offs. Univariate analysis of baseline factors associated with a biologics prescription was performed using Pearson's v 2 -test. In the case of ordinal data, a Cochran-Armitage test for linear trend was also performed across different levels of variables. All of the variables with a P-value < 0Á10 from the univariate analysis were considered for inclusion in the multivariate analysis. A multiple logistic regression with a forward stepwise algorithm selection was used to identify significant predictors of a biological prescription. The effects of the identified factors were expressed in terms of an odds ratio (OR) with 95% confidence interval (CI) and P-value. When required, the effect of interaction between selected variables was tested. Multiple logistic regression models were additionally used to adjust the effects of selected factors on severe psoriasis conditions (PASI score > 20). Patients with missing data were excluded from the analysis. When planning this study we considered that with 12 838 patients fulfilling inclusion/exclusion criteria at the time of data extraction we could detect OR > 1Á18 in multiple logistic regression models (ratio of control to case group of 1Á35, proportion of exposure in control group > 10% and multiple correlation coefficient < 0Á3, a = 0Á05, b = 0Á2).
In addition, the associations among variables were analysed by means of an artificial adaptive system, the auto contractive map (AutoCM). 9 AutoCM is a data mining tool based on an artificial neural network (ANN) model that is especially effective at highlighting any patterns and/or systematic relationships and hidden trends among variables. The weights determined by AutoCM are proportional to the strength of the associations across all of the variables. The weights are transformed into distances, and a mathematical filter [the minimum spanning tree (MST)] 10 is applied to the matrix of the distances. A semantic connectivity map is then generated from the MST. In the connectivity map, hubs of variables are detected, and related dependent variables converge to these hubs. The system also provides a quantification of the strength of links among variables by a numerical coefficient ranging from 0 (minimum strength) to 1 (maximum strength). All of the tests were considered significant at a P-value < 0Á05. Analyses were performed with SPSS IBM software, version 20 (IBM Corp., Armonk, NY, U.S.A.) and AutoCM software, version 7 (Semeion Research Centre, Rome, Italy).
Results
Overall, from September 2005 to September 2009, 12 838 patients fulfilling the study inclusion criteria were identified. The general characteristics of the patients are reported in Table 1 . Mean age AE SD was 48Á8 AE 14Á4 years, with a male : female ratio of 1Á9. Mean body mass index (BMI) was 27Á0 AE 4Á9 kg m À2 and prevalence of smokers and regular drinkers was 40Á2% and 35Á7%, respectively. Most patients (70Á7%) were married, had attained lower or upper secondary education (33Á3% and 38Á9%, respectively) and worked as employees, craftsmen or skilled workers (32Á5%). Mean PASI score was 17Á2 AE 10Á5, with an average disease duration of 16Á9 AE 13Á0 years and a mean CCI of 0Á29 AE 0Á78. PsA and pustular psoriasis were present in 24Á8% and 2Á9% of the patients, respectively. Prescribed drugs at entry in the registry were etanercept (29Á0%), ciclosporin (27Á3%), acitretin (14Á7%), methotrexate (11Á7%), infliximab (8Á8%), adalimumab (4Á9%) and PUVA therapy (3Á8%). The overall rate of biological drug prescriptions was 42Á5%.
Analysis of variables associated with biological drug prescriptions
All of the factors with a P-value < 0Á10 in the univariate analysis (Table 1) ; ex-/nonsmoker or ex-/nondrinker status; being visited in central/southern Italy; educational attainment higher than lower secondary school; employment as a manager or a professional; calendar year of visit (with a significant increasing trend over time); PASI score > 10; positive history of hypertension or negative history of neoplasms; absence of pustular psoriasis or presence of PsA; number of previous systemic treatments for psoriasis (with a substantial growing trend with increasing numbers); and any hospital admission for psoriasis in the last 5 years were all associated with biologic prescriptions at entry in the registry. Interestingly, educational attainment was shown to be an independent predictive factor, with a clear increasing trend of biological drug prescriptions towards higher education. This was further confirmed by a higher employment status. Additional analyses on the association between these two variables and a severe psoriasis condition (PASI score > 20) revealed a significant increasing trend of severe disease towards lower educational attainment, while unemployed patients were more likely to have a more severe condition compared with other categories of workers, including managers and professionals (Table 2) . Furthermore, we assessed the interaction between geographical area and both employment status and educational attainment. While the former was not significant, the latter was an effect modifier for prescription of biological therapies, with education having more impact on outcome in the northern area compared with central/southern regions (data not shown).
Auto contractive map analysis Figure 1 shows the map produced by the AutoCM algorithm. The algorithm highlights the main associations between variables in the database, offering a simple graphical way to display their mutual interaction. The resulting map can be divided into three regions. In the first and second regions, at the top and bottom, respectively, the variables are connected to conventional and biological drug prescriptions, respectively, at entry in the registry. Both of the variables act as main hubs in the system. Being a smoker or a drinker, being 60 years old or more, being overweight or obese, having any history of main comorbidities (except for chronic liver diseases or a short duration of disease) and being fairly na€ ıve to systemic treatments were all factors connected to conventional prescriptions. Unskilled workers and those with primary or lower secondary school degrees were also associated with conventional drug use. These results confirmed those of the main analysis.
Conversely, at the bottom of the map, having severe psoriasis or mild psoriasis associated with PsA, being a nonresponder to previous systemic treatments or being admitted to a hospital for psoriasis in the last 5 years were all associated with biological therapy prescriptions. In addition, being a manager or having at least a university degree was confirmed to be associated with biological drug use. Finally, the middle region of the map captures other, less relevant pieces of information, which are common to most of the patients included.
Discussion
Targeted biological therapies have represented a breakthrough in the management of patients with psoriasis. These drugs are much more expensive than conventional agents, and use of biologics is restricted to patients with contraindications to or side-effects from conventional agents. The aim of our study was to investigate the determinants that influenced the prescription of systemic conventional treatments compared with biological treatments for patients with moderate-to-severe psoriasis, based on data from the Psocare registry. In our study, fewer than half of the patients received a biological treatment for their psoriasis. We documented an increasing trend in the number of prescriptions of biological agents with a higher education and employment status of the patients. Conversely, unemployed patients and patients with lower educational attainment were less likely to receive a prescription of a biological agent. These differences were not accounted for by other factors, such as disease severity or lifestyle issues. As a matter of fact, unemployed and less educated patients had a higher chance of presenting at baseline with a more severe cutaneous condition (PASI score > 20) compared with the other patients. A similar result was found in a study by Horn et al., 11 where patients with severe psoriasis were more likely to have lower household income, although information on severity and income was self-reported by the patient. Our results were confirmed in a secondary analysis performed by using ANN systems. The main advantage of this analysis is the possibility of presenting, in a single map, the mutual associations among all the variables in the registry. A possible disadvantage, however, is that the higher complexity of the model, compared with the classical approach used in the main analysis, requires a larger sample size in order to achieve sufficient generalizability of results.
Socioeconomic status is traditionally composed of three dimensions: educational attainment, occupation and household income. Education in combination with occupation are the most frequently used indicators. Household income may be difficult to obtain due to privacy restriction. However, it has been shown that higher levels of education are associated with better economic outcomes, 12 while occupational status reflects the educational attainment required to obtain the job and income levels, so that it encompasses both income and educational attainment. 13 In our study, we did not collect other variables that might contribute to the definition of wealth such as household income, family size, religion and ethnicity. A significant trend for the penetration of biological therapies over time was observed from 2005 to 2009 in our registry, but the increased penetration did not temper the effect of inequalities in biologics prescription. The Italian NHS is expected to guarantee uniform care throughout the country. Public healthcare spending, in the last 25 years, has consistently exceeded central government forecasts, and the expectation is that resources be allocated fairly in a way that permits equal access to care for all individuals registered for it.
14 Even if it is understandable that information on new therapies could be more available to those people who are younger, those with a higher level of education and those with a higher socioeconomic status, it is not expected that those factors could influence prescriptions by treating physicians. It can be also hypothesized that higher socioeconomic status and education might be associated with better negotiation skills or increased empathy from physicians, although further research is needed to clarify these points. It should be noted that in our study all of the consecutive patients receiving a first prescription of a new systemic agent and being seen at a network of dermatological centres were enrolled, and a selection bias is unlikely. 15 Health inequalities have been defined as systematic unfair differences in care that are preventable by reasonable action. 16 Inequalities have been documented in clinical care for selected skin conditions, such as skin cancer and atopic dermatitis. 3, [17] [18] [19] [20] [21] [22] [23] Two previous experiences from the U.S.A. have documented the impact of socioeconomic factors on drug prescriptions in psoriasis. One study from the Medicare program showed that people without access to a Medicare Part D low-income subsidy had a 70% lower odds of receiving biologics than those with access to Medicare. A similar low chance was also observed for black patients compared with white patients. 5 Another study, limited to a single academic medical centre, documented that difficulty in obtaining biologics was associated with younger age, lower income level and lack of insurance. 6 Interestingly, a study based on data from the PsoReg registry in Sweden documented that patients with psoriasis had fewer opportunities to access biological medications as they age. 24 The study made adjustment for educational level but not for income.
In agreement with data from the two studies from the U.S.A. we documented disparities of care in psoriasis in Italy, with prescription of biological agents being more frequent in higher socioeconomic sectors of the population. We did not assess if disparity of prescription translated into differences in the clinical outcome or comorbidities over time. Such an issue should be considered in future studies.
Ideally, everybody should expect an identical standard of care. The aim of policy for equity is to reduce or eliminate those disparities, which are considered to be both avoidable and unfair. 4 There are some possible actions to reduce inequalities in healthcare provisions for patients with psoriasis, including patient education and auditing of clinical decisions. Recently, the American Academy of Dermatology created the Access to Dermatologic Care Task Force to foster the consciousness of dermatologists about the disparities affecting minority populations because of race or ethnicity, socioeconomic status, geography, sex, age and disability status, and to cultivate policies that improve these people's access to dermatological services. 3 Similar actions should be implemented in other countries as well.
To summarize, we documented the inequalities in drug prescriptions for psoriasis in Italy and found a trend towards a higher number of prescriptions for more expensive biologics in higher socioeconomic sectors of the population. This is unfair considering that drugs are paid for by the money of the National Health System, to which all Italian citizens contribute.
